Deal covers active components of MultiCell’s treatment for chronic fatigue.
MultiCell Technologies entered into a long-term agreement with Lundbeck Pharmaceuticals Italy related to its multiple sclerosis (MS) drug. Lundbeck will supply one of the active components of MCT-125, which is in a Phase IIb study for the treatment of chronic fatigue in patients with MS.
In a 138-patient, multicenter, double-blind, placebo-controlled Phase II trial conducted in the U.K. by Amarin, MCT-125 (then known as LAX-202) demonstrated efficacy in significantly reducing the levels of fatigue in MS patients, notes MultiCell.
MCT-125 demonstrated effectiveness within four weeks of the first daily oral dosing and showed efficacy in all MS patient subpopulations, including relapsing-remitting, secondary progressive, and primary progressive. Patients enrolled in the Phase II trial conducted by Amarin also reported few if any side effects following daily oral dosing of MCT-125.
